Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Multiple Myeloma"
topic_facet:"Recruitment Status: Completed"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Multiple+Myeloma%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Completed%22&lookfor=%22Myeloma%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Multiple+Myeloma%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Completed%22&lookfor=%22Myeloma%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Multiple+Myeloma%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Completed%22&lookfor=%22Myeloma%22&type=Subject
PubPharm (1.194)
1
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma : Comparative Effectiveness of Elranatamab (PF 06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in Real-World (RW) External Control Arms in Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
2
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) : A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Chinese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed At Least Two Lines of Previous Treatment, Containing an Alkylator, a Proteasome Inhibitor and an Immunomodulatory Agent
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
3
Natural Killer Cells and Bortezomib to Treat Cancer : Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With Bortezomib
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
4
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions : A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
5
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma : A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
6
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma : A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
7
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant : A Feasibility Study of Chaplain-Delivered Compassion Meditation for Patients Receiving Stem Cell Transplantation
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
8
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma : LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Phase I/II Study of Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
9
Stage I Multiple Myeloma Treatment : Stage I Multiple Myeloma Treatment
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
10
A Real-World Study of Bispecific Antibodies in Multiple Myeloma : A Real-World Study of Bispecific Antibodies, Teclistamab and Elranatamab, for Patients With Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[120]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Multiple Myeloma
Filter aufheben
Thema: Recruitment Status: Completed
Medienart
1.194
Aufsätze
1.194
E-Artikel
1.194
E-Ressourcen
Zeitschriftentitel
1.194
ClinicalTrials.gov
Thema
1.194
610
Multiple Myeloma
Recruitment Status: Completed
1.024
Study Type: Interventional
992
Neoplasms, Plasma Cell
436
Medical Condition: Multiple Myeloma
382
Phase: Phase 2
265
Phase: Phase 1
182
Lymphoma
167
Study Type: Observational
158
Leukemia
125
Myelodysplastic Syndromes
113
Phase: Phase 3
94
Phase: Phase 1/Phase 2
86
Leukemia, Lymphocytic, Chronic, B-Cell
84
Lymphoma, Non-Hodgkin
74
Plasmacytoma
73
Preleukemia
68
Leukemia, Lymphoid
67
Myeloproliferative Disorders
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
505
2020-
658
2010-2019
31
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
1.194
Englisch
Haven't found what you're looking for?
Wird geladen...